AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• AnaptysBio, Inc. (NASDAQ:ANAB) has received a consensus rating of “Moderate Buy” from ten analysts, with three holding, six buying, and one strongly buying the stock.
• The average one-year target price for AnaptysBio's stock among brokerages is $46.13, demonstrating positive market sentiment towards the company's prospects.
• In the latest earnings report, AnaptysBio beat consensus EPS estimates, reporting ($1.34) compared to the expected ($1.50), with revenue significantly exceeding expectations at $22.26 million.

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $46.1250.

ANAB has been the subject of several recent analyst reports. Guggenheim restated a "buy" rating and set a $90.00 price objective (up from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. JPMorgan Chase & Co. raised their price objective on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a research report on Thursday, July 24th. UBS Group restated a "neutral" rating and set a $20.00 price objective (up from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. Wedbush raised their price objective on shares of AnaptysBio from $40.00 to $45.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. Finally, HC Wainwright upgraded shares of AnaptysBio from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $22.00 to $38.00 in a research report on Wednesday, June 4th.

AnaptysBio Stock Up 0.9%

Shares of NASDAQ ANAB opened at $23.40 on Friday. The firm has a 50-day simple moving average of $23.07 and a 200-day simple moving average of $21.07. The stock has a market capitalization of $655.20 million, a price-to-earnings ratio of -5.22 and a beta of -0.19. AnaptysBio has a 52 week low of $12.21 and a 52 week high of $40.70.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) EPS for the quarter, beating analysts' consensus estimates of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The business had revenue of $22.26 million during the quarter, compared to analysts' expectations of $11.55 million. As a group, equities research analysts expect that AnaptysBio will post -6.08 EPS for the current year.

Insider Transactions at AnaptysBio

In related news, Director Hollings Renton sold 20,925 shares of the firm's stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the completion of the sale, the director directly owned 4,965 shares in the company, valued at approximately $117,025.05. This trade represents a 80.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 33.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. US Bancorp DE boosted its stake in AnaptysBio by 126.5% during the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after buying an additional 979 shares during the period. Farther Finance Advisors LLC boosted its stake in AnaptysBio by 9,778.9% during the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock worth $35,000 after buying an additional 1,858 shares during the period. Tower Research Capital LLC TRC boosted its stake in AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock worth $48,000 after buying an additional 1,377 shares during the period. Osaic Holdings Inc. boosted its stake in AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock worth $52,000 after buying an additional 2,326 shares during the period. Finally, GAMMA Investing LLC purchased a new position in AnaptysBio during the first quarter worth about $113,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.